In addition, editing of GLI1 by ADAR1 resulted in an increased proportion of drug-resistant cells in myeloma, suggesting that inhibition of GLI1 editing by ADAR1 could improve the sensitivity of myeloma cells to drug therapy [111, 124]. Here, ADAR is linked to plasma cell myeloma.